Issues
-
Cover Image
Cover Image
Top image: Schumacher et al. replicated the overall association between an 8q24 single nucleotide polymorphism (rs1447295) and prostate cancer risk previously identified by two independent studies in a large pooled analysis from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3) using 6,637 prostate cancer cases and 7,361 matched controls. The odds ratios and 99% CI for prostate cancer are presented among Caucasians in the middle panel and the corresponding -Log p-values from the two degrees-of-freedom LRT are shown in the right panel. The overall prostate cancer risk in Caucasians was 1.34 (99%CI: 1.19, 1.50) in men with one copy of the minor allele (A) and 1.86 (99%CI: 1.30, 2.67) in men with two copies of the minor allele compared with wild-type homozygotes (LRT p=1.23 x 10-13). The authors found no significant association between this polymorphism and breast cancer among 2,604 Caucasian breast cancer cases and 3,118 matched controls in BPC3. Our large sample size leaves little room for the possibility of a false-positive result between this locus and prostate cancer risk.
Bottom image: Wang et al. It is well accepted that genetics plays an important role in prostate cancer. However, due to the complex nature of this disease, the identification of candidate susceptibility genes has been enormously challenging. Recently, using both linkage and association-based analyses, Amundadottir et al. identified a region on chromosome 8q24 showing suggestive linkage to prostate cancer and further identified two common variants (rs1447295/DG8S737) associated with prostate cancer risk. In a study comprising 1,121 men with prostate cancer (435 men with familial prostate cancer, 491 men with sporadic prostate cancer, and 195 men with aggressive prostate cancer) and 545 population-based controls, Wang et al. present data replicating these findings reported by Amundadottir et al. Given the historical difficulty in replicating both linkage and gene association studies in prostate cancer, these confirmatory findings provide important clues towards the identification of candidate genetic susceptibility factors. The functional significance of the two polymorphic variants, however, remains unclear and is the subject of ongoing research. The figure (generated from UCSC genome browser) illustrates the location of the two variants (DG8S737 and rs1447295) along with the position of known genes, predicted genes, mRNAs, and a linkage disequilibrium map in the region of interest covering ~500Kb.
For details, see the articles by Schumacher et al. on page 2951 and Wang et al. on page 2944, as well as a commentary on these findings by Dr. Elizabeth A. Platz on page 2905 of this issue. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Commentary
Reviews
Priority Reports
A Common 8q24 Variant in Prostate and Breast Cancer from a Large Nested Case-Control Study
Molecular Biology, Pathobiology, and Genetics
Aurora A and B Overexpression and Centrosome Amplification in Early Estrogen-Induced Tumor Foci in the Syrian Hamster Kidney: Implications for Chromosomal Instability, Aneuploidy, and Neoplasia
Fatty Acid Synthase Inhibition Activates AMP-Activated Protein Kinase in SKOV3 Human Ovarian Cancer Cells
Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling
Hyperthermia Activates a Subset of Ataxia-Telangiectasia Mutated Effectors Independent of DNA Strand Breaks and Heat Shock Protein 70 Status
Tagging Single Nucleotide Polymorphisms in Cell Cycle Control Genes and Susceptibility to Invasive Epithelial Ovarian Cancer
Cell, Tumor, and Stem Cell Biology
Effect of Human Skin-Derived Stem Cells on Vessel Architecture, Tumor Growth, and Tumor Invasion in Brain Tumor Animal Models
RaLP, a New Member of the Src Homology and Collagen Family, Regulates Cell Migration and Tumor Growth of Metastatic Melanomas
E-Cadherin Cell-Cell Adhesion in Ewing Tumor Cells Mediates Suppression of Anoikis through Activation of the ErbB4 Tyrosine Kinase
Identification of Putative Stem Cell Markers, CD133 and CXCR4, in hTERT–Immortalized Primary Nonmalignant and Malignant Tumor-Derived Human Prostate Epithelial Cell Lines and in Prostate Cancer Specimens
Detection of DNA Copy Number Changes and Oncogenic Signaling Abnormalities from Gene Expression Data Reveals MYC Activation in High-Grade Papillary Renal Cell Carcinoma
Experimental Therapeutics, Molecular Targets, and Chemical Biology
Gene and Protein Expression Profiling of Human Ovarian Cancer Cells Treated with the Heat Shock Protein 90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin
IFN-γ Enhances the Antimyeloma Activity of the Fully Human Anti–Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3
Repression of IFN Regulatory Factor 8 by DNA Methylation Is a Molecular Determinant of Apoptotic Resistance and Metastatic Phenotype in Metastatic Tumor Cells
Enhanced Expression of Asparagine Synthetase under Glucose-Deprived Conditions Protects Pancreatic Cancer Cells from Apoptosis Induced by Glucose Deprivation and Cisplatin
Immunology
Endocrinology
Clinical Research
Phosphoprotein Pathway Mapping: Akt/Mammalian Target of Rapamycin Activation Is Negatively Associated with Childhood Rhabdomyosarcoma Survival
Relation of a Hypoxia Metagene Derived from Head and Neck Cancer to Prognosis of Multiple Cancers
A High-Throughput Study in Melanoma Identifies Epithelial-Mesenchymal Transition as a Major Determinant of Metastasis
Autoantibody Profiles Reveal Ubiquilin 1 as a Humoral Immune Response Target in Lung Adenocarcinoma
Epidemiology and Prevention
Corrections
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.